Sarcoidosis drug study halted after only 2 patients enrolled
NCT ID NCT02523092
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether Acthar gel could improve symptoms and lung function in people with sarcoidosis, a disease that causes inflammation in the lungs. Researchers also checked if a blood marker called CXCL9 could predict how well the treatment works. Only 2 people joined before the study was stopped early, so the results are very limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scans may unlock hidden risks in minority communities
- Can immune profiling unlock the hidden stages of tuberculosis?
- Can a new infusion drug tame lung inflammation and cut steroid use?
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Experimental drug aims to improve breathing in lung sarcoidosis
- Home devices may spot lung flare-ups before they become emergencies